Our study identifies several potential predictors of response to STZ with at least one end-point with statistical significance: age, CgA blood levels, tumor grade, Ki-67% index, anatomical location of the primary tumor, tumor stage, site of metastasis origin, liver tumor burden, extrahepatic spread, functional status, MGMT status, line of therapy, and response to previous treatments. The gene discussed is MKI67; the disease is neoplasm.